ClinicalTrials.gg
CompletedNCT07049939Updated Feb 25, 2026

A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)

A Phase 1 interventional study of Bomedemstat in Hepatic Insufficiency, sponsored by Merck Sharp & Dohme LLC. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Hepatic Insufficiency by Merck & Co., Inc — 1 open to participants now, 1 under way, none of them phase 3. Hepatic Insufficiency · Merck & Co., Inc.

Enrollment
9th of 10
9 · median 20
Started
2025
the only one that year
Phase 1
10 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Hepatic Insufficiency by Merck & Co., Inc, this one is the 9th largest by enrollment, is the only one that started in 2025, is one of 10 in phase 1, and was the 10th registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

1 of the 10 studies in Hepatic Insufficiency by Merck & Co., Inc is open now. Recruiting first, the newest first:

Where they have run

Who these studies take

Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hepatic Insufficiency by Merck & Co., Inc, or all of them as a file.
02

Study summary

The purpose of this study is to learn what happens to bomedemstat (MK-3543) in a person's body over time. Researchers will compare what happens to bomedemstat in the body when it is given to participants with mild or moderate hepatic (liver) impairment and healthy participants.

Participants will be allocated to one of three groups: mild hepatic impairment (HI), moderate HI, or healthy matched control. All participants will receive a single oral dose of bomedemstat on Day 1.

Healthy control participants will be enrolled after hepatic impairment participants have been dosed. Healthy control participants will be matched for the mean age and mean body-mass index (BMI) of all participants with HI (mild and moderate HI combined) and sex to each HI group separately.

03

Conditions studied

  • Hepatic Insufficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Is a non-smoker or is a moderate smoker for at least 3 months prior to dosing

Participants with Mild and Moderate HI

  • Is classified as having either mild HI (Group 1) or moderate HI (Group 2) score on the scale ranging from 5 to 6 (mild) or 7 to 9 (moderate)
  • Has a diagnosis of chronic (> 6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in hepatic function) hepatic insufficiency with features of cirrhosis due to any etiology

Healthy Control Participants:

  • Must match the mean age (± 15 years) of participants with mild HI and moderate HI
  • Must match the mean body-mass index () (± 25%) of participants with mild HI (Group 1) and moderate HI
  • Must match the sex ratio (±2) of participants in each HI group, separately

Exclusion criteria

Exclusion Criteria

The main exclusion criteria include but are not limited to the following:

All Participants

  • History of cancer ()
  • Female participants of
  • Is positive for virus (HCV)
  • Is positive for surface antigen (HBsAg)
  • Is positive for (HIV)

Participants with Mild and Moderate HI

  • Has any significant arrhythmia or conduction abnormality
  • Severe complications of liver disease within the preceding 3 months
  • Primary biliary cholangitis or biliary obstruction
  • Has a history of a recent variceal bleeds
  • Has evidence of hepatorenal syndrome
  • Has a history of liver or other solid organ transplantation
  • Has an active infection requiring systemic therapy
  • Requires paracentesis more often than 2 times per month
  • Has transjugular intrahepatic portosystemic shunt and/or has undergone portacaval shunting

Healthy Control Participants

  • Has a history of endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Is a regular user of cannabis products within approximately 6 months of study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Mild Hepatic Impairment

    Participants with mild hepatic impairment will receive a single oral 25 mg dose of bomedemstat on Day 1.

    Drug: Bomedemstat

  • Experimental
    Moderate Hepatic Impairment

    Participants with mild hepatic impairment will receive a single oral 25 mg dose of bomedemstat on Day 1.

    Drug: Bomedemstat

  • Experimental
    Healthy Matched Control

    Healthy participants will receive a single oral 25 mg dose of bomedemstat on Day 1.

    Drug: Bomedemstat

Interventions

  • Capsule for oral administration

    Also known as: MK-3543

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Bomedemstat in Participants with Mild Hepatic Impairment (HI)

    Blood samples collected to determine the AUC0-inf of bomedemstat.

    Time frame: Up to 216 hours

  2. Maximum Plasma Concentration (Cmax) of Bomedemstat in Participants with Mild HI

    Blood samples collected to determine the Cmax of bomedemstat.

    Time frame: Up to 216 hours

  3. AUC0-Inf of Bomedemstat in Participants with Moderate HI

    Blood samples collected to determine the AUC0-inf of bomedemstat.

    Time frame: Up to 216 hours

  4. Cmax of Bomedemstat in Participants with Moderate HI

    Blood samples collected to determine the Cmax of bomedemstat.

    Time frame: Up to 216 hours

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported.

    Time frame: Up to 14 days

  2. Number of Participants Who Discontinue Study Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to an AE will be reported.

    Time frame: Up to 14 days

  3. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Bomedemstat in Participants with Mild HI

    Blood samples will be collected to determine the AUC0-last of bomedemstat.

    Time frame: Up to 216 hours

  4. Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hrs) of Bomedemstat in Participants with Mild HI

    Blood samples will be collected to determine the AUC0-24hr of bomedemstat.

    Time frame: At designated timepoints up to 24 hours postdose

  5. Plasma Concentration at 24 Hours (C24) of Bomedemstat in Participants with Mild HI

    Blood samples will be collected to determine the C24 of bomedemstat.

    Time frame: At designated timepoints up to 24 hours postdose

  6. Time to Maximum Plasma Concentration (Tmax) of Bomedemstat in Participants with Mild HI

    Blood samples will be collected to determine the Tmax of bomedemstat.

    Time frame: Up to 216 hours

  7. Apparent Terminal Half-life (t1/2) of Bomedemstat in Participants with Mild HI

    Blood samples will be collected to determine the t1/2 of bomedemstat.

    Time frame: Up to 216 hours

  8. Apparent Clearance (CL/F) of Bomedemstat in Participants with Mild HI

    Blood samples will be collected to determine the CL/F of bomedemstat.

    Time frame: Up to 216 hours

  9. Apparent Volume of Distribution During Terminal Phase (Vz/F) of Bomedemstat in Participants with Mild HI

    Blood samples will be collected to determine the Vz/F of bomedemstat.

    Time frame: Up to 216 hours

  10. AUC0-Last of Bomedemstat in Participants with Moderate HI

    Blood samples will be collected to determine the AUC0-last of bomedemstat.

    Time frame: Up to 216 hours

  11. AUC0-24hrs of Bomedemstat in Participants with Moderate HI

    Blood samples will be collected to determine the AUC0-24hr of bomedemstat.

    Time frame: At designated timepoints up to 24 hours postdose

  12. C24 of Bomedemstat in Participants with Moderate HI

    Blood samples will be collected to determine the C24 of bomedemstat.

    Time frame: At designated timepoints up to 24 hours postdose

  13. Tmax of Bomedemstat in Participants with Moderate HI

    Blood samples will be collected to determine the Tmax of bomedemstat.

    Time frame: Up to 216 hours

  14. t1/2 of Bomedemstat in Participants with Moderate HI

    Blood samples will be collected to determine the t1/2 of bomedemstat.

    Time frame: Up to 216 hours

  15. CL/F of Bomedemstat in Participants with Moderate HI

    Blood samples will be collected to determine the CL/F of bomedemstat.

    Time frame: Up to 216 hours

  16. Vz/F of Bomedemstat in Participants with Moderate HI

    Blood samples will be collected to determine the Vz/F of bomedemstat.

    Time frame: Up to 216 hours

07

Study locations

3 sites
  • University of Miami ( Site 0003)
    Miami, Florida 33136, United States
  • Orlando Clinical Research Center ( Site 0001)
    Orlando, Florida 32809, United States
  • The Texas Liver Institute ( Site 0002)
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Feb 2026, 5 months.

Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 5 months is below that.

Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2025
First posted
Jul 3, 2025
StartActual
Aug 20, 2025
Primary completionActual
Feb 17, 2026
CompletionActual
Feb 17, 2026
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07049939
Responsible party
Sponsor
First posted
Jul 3, 2025
Start date
Aug 20, 2025
Primary completion
Feb 17, 2026
Completion
Feb 17, 2026
Last update
Feb 25, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bomedemstat

Start the discussion